590 related articles for article (PubMed ID: 32432388)
1. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Yazici Y; McAlindon TE; Gibofsky A; Lane NE; Clauw D; Jones M; Bergfeld J; Swearingen CJ; DiFrancesco A; Simsek I; Tambiah J; Hochberg MC
Arthritis Rheumatol; 2020 Oct; 72(10):1694-1706. PubMed ID: 32432388
[TBL] [Abstract][Full Text] [Related]
2. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.
Yazici Y; McAlindon TE; Fleischmann R; Gibofsky A; Lane NE; Kivitz AJ; Skrepnik N; Armas E; Swearingen CJ; DiFrancesco A; Tambiah JRS; Hood J; Hochberg MC
Osteoarthritis Cartilage; 2017 Oct; 25(10):1598-1606. PubMed ID: 28711582
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
Deshmukh V; O'Green AL; Bossard C; Seo T; Lamangan L; Ibanez M; Ghias A; Lai C; Do L; Cho S; Cahiwat J; Chiu K; Pedraza M; Anderson S; Harris R; Dellamary L; Kc S; Barroga C; Melchior B; Tam B; Kennedy S; Tambiah J; Hood J; Yazici Y
Osteoarthritis Cartilage; 2019 Sep; 27(9):1347-1360. PubMed ID: 31132406
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.
Yazici Y; McAlindon TE; Gibofsky A; Lane NE; Lattermann C; Skrepnik N; Swearingen CJ; Simsek I; Ghandehari H; DiFrancesco A; Gibbs J; Tambiah JRS; Hochberg MC
Osteoarthritis Cartilage; 2021 May; 29(5):654-666. PubMed ID: 33588087
[TBL] [Abstract][Full Text] [Related]
5. Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint.
Tambiah JRS; Simsek I; Swearingen CJ; Kennedy S; Cole BJ; McAlindon TE; Yazici Y
Am J Sports Med; 2022 Mar; 50(3):630-636. PubMed ID: 35005990
[TBL] [Abstract][Full Text] [Related]
6. Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial.
Tambiah JRS; Kennedy S; Swearingen CJ; Simsek I; Yazici Y; Farr J; Conaghan PG
Rheumatol Ther; 2021 Jun; 8(2):973-985. PubMed ID: 34101138
[TBL] [Abstract][Full Text] [Related]
7. Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug.
Sabha M; Siaton BC; Hochberg MC
Expert Opin Investig Drugs; 2020 Dec; 29(12):1339-1346. PubMed ID: 33096010
[No Abstract] [Full Text] [Related]
8. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.
Lohmander LS; Hellot S; Dreher D; Krantz EF; Kruger DS; Guermazi A; Eckstein F
Arthritis Rheumatol; 2014 Jul; 66(7):1820-31. PubMed ID: 24740822
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomized, double-blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee.
Petrella RJ; Petrella M
J Rheumatol; 2006 May; 33(5):951-6. PubMed ID: 16652426
[TBL] [Abstract][Full Text] [Related]
10. Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial.
Petterson SC; Plancher KD
Knee Surg Sports Traumatol Arthrosc; 2019 Jun; 27(6):1992-2002. PubMed ID: 30159738
[TBL] [Abstract][Full Text] [Related]
11. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study.
Krupka E; Jiang GL; Jan C
Osteoarthritis Cartilage; 2019 Nov; 27(11):1599-1607. PubMed ID: 31351965
[TBL] [Abstract][Full Text] [Related]
13. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis.
Langworthy MJ; Conaghan PG; Ruane JJ; Kivitz AJ; Lufkin J; Cinar A; Kelley SD
Adv Ther; 2019 Jun; 36(6):1398-1411. PubMed ID: 30968336
[TBL] [Abstract][Full Text] [Related]
15. Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study.
Conaghan PG; Hunter DJ; Cohen SB; Kraus VB; Berenbaum F; Lieberman JR; Jones DG; Spitzer AI; Jevsevar DS; Katz NP; Burgess DJ; Lufkin J; Johnson JR; Bodick N;
J Bone Joint Surg Am; 2018 Apr; 100(8):666-677. PubMed ID: 29664853
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study.
McAlindon TE; Schmidt U; Bugarin D; Abrams S; Geib T; DeGryse RE; Kim K; Schnitzer TJ
Osteoarthritis Cartilage; 2018 Oct; 26(10):1291-1299. PubMed ID: 29753118
[TBL] [Abstract][Full Text] [Related]
17. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study.
Chevalier X; Goupille P; Beaulieu AD; Burch FX; Bensen WG; Conrozier T; Loeuille D; Kivitz AJ; Silver D; Appleton BE
Arthritis Rheum; 2009 Mar; 61(3):344-52. PubMed ID: 19248129
[TBL] [Abstract][Full Text] [Related]
18. Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Roman-Blas JA; Castañeda S; Sánchez-Pernaute O; Largo R; Herrero-Beaumont G;
Arthritis Rheumatol; 2017 Jan; 69(1):77-85. PubMed ID: 27477804
[TBL] [Abstract][Full Text] [Related]
19. OA phenotypes, rather than disease stage, drive structural progression--identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA.
Karsdal MA; Bihlet A; Byrjalsen I; Alexandersen P; Ladel C; Michaels M; Andersen JR; Riis BJ; Kraus V; Bay-Jensen AC; Christiansen C
Osteoarthritis Cartilage; 2015 Apr; 23(4):550-8. PubMed ID: 25576879
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Diclofenac-Hyaluronate Conjugate (Diclofenac Etalhyaluronate) for Knee Osteoarthritis: A Randomized Phase III Trial in Japan.
Nishida Y; Kano K; Nobuoka Y; Seo T
Arthritis Rheumatol; 2021 Sep; 73(9):1646-1655. PubMed ID: 33749997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
